These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 25435179)

  • 1. Sirtuin modulators: an updated patent review (2012 - 2014).
    Mellini P; Valente S; Mai A
    Expert Opin Ther Pat; 2015 Jan; 25(1):5-15. PubMed ID: 25435179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A patent review of sirtuin activators: an update.
    Villalba JM; de Cabo R; Alcain FJ
    Expert Opin Ther Pat; 2012 Apr; 22(4):355-67. PubMed ID: 22475539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer agents targeted to sirtuins.
    Kozako T; Suzuki T; Yoshimitsu M; Arima N; Honda S; Soeda S
    Molecules; 2014 Dec; 19(12):20295-313. PubMed ID: 25486244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirtuin modulators.
    Mahajan SS; Leko V; Simon JA; Bedalov A
    Handb Exp Pharmacol; 2011; 206():241-55. PubMed ID: 21879453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirtuin modulators: where are we now? A review of patents from 2015 to 2019.
    Mautone N; Zwergel C; Mai A; Rotili D
    Expert Opin Ther Pat; 2020 Jun; 30(6):389-407. PubMed ID: 32228181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sirtuin activators and inhibitors.
    Villalba JM; Alcaín FJ
    Biofactors; 2012; 38(5):349-59. PubMed ID: 22730114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Sirtuin family: therapeutic targets to treat diseases of aging.
    Milne JC; Denu JM
    Curr Opin Chem Biol; 2008 Feb; 12(1):11-7. PubMed ID: 18282481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of activators and inhibitors of sirtuins.
    Balcerczyk A; Pirola L
    Biofactors; 2010; 36(5):383-93. PubMed ID: 20848588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirtuin functions and modulation: from chemistry to the clinic.
    Carafa V; Rotili D; Forgione M; Cuomo F; Serretiello E; Hailu GS; Jarho E; Lahtela-Kakkonen M; Mai A; Altucci L
    Clin Epigenetics; 2016; 8():61. PubMed ID: 27226812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirtuin activators.
    Alcaín FJ; Villalba JM
    Expert Opin Ther Pat; 2009 Apr; 19(4):403-14. PubMed ID: 19441923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of 1,4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors.
    Mai A; Valente S; Meade S; Carafa V; Tardugno M; Nebbioso A; Galmozzi A; Mitro N; De Fabiani E; Altucci L; Kazantsev A
    J Med Chem; 2009 Sep; 52(17):5496-504. PubMed ID: 19663498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirtuin 1 (SIRT1): the misunderstood HDAC.
    Stünkel W; Campbell RM
    J Biomol Screen; 2011 Dec; 16(10):1153-69. PubMed ID: 22086720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.
    Qin HT; Li HQ; Liu F
    Expert Opin Ther Pat; 2017 May; 27(5):621-636. PubMed ID: 28033734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SIRTUIN 1: regulating the regulator.
    Zschoernig B; Mahlknecht U
    Biochem Biophys Res Commun; 2008 Nov; 376(2):251-5. PubMed ID: 18774777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New assays and approaches for discovery and design of Sirtuin modulators.
    Schutkowski M; Fischer F; Roessler C; Steegborn C
    Expert Opin Drug Discov; 2014 Feb; 9(2):183-99. PubMed ID: 24382304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenylyl cyclases as innovative therapeutic goals.
    Pavan B; Biondi C; Dalpiaz A
    Drug Discov Today; 2009 Oct; 14(19-20):982-91. PubMed ID: 19638320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based drug design of small molecule SIRT1 modulators to treat cancer and metabolic disorders.
    Pulla VK; Alvala M; Sriram DS; Viswanadha S; Sriram D; Yogeeswari P
    J Mol Graph Model; 2014 Jul; 52():46-56. PubMed ID: 25000096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 1.
    Kelly G
    Altern Med Rev; 2010 Sep; 15(3):245-63. PubMed ID: 21155626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 2.
    Kelly GS
    Altern Med Rev; 2010 Dec; 15(4):313-28. PubMed ID: 21194247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SIRT1-independent mechanisms of the putative sirtuin enzyme activators SRT1720 and SRT2183.
    Huber JL; McBurney MW; Distefano PS; McDonagh T
    Future Med Chem; 2010 Dec; 2(12):1751-9. PubMed ID: 21428798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.